Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting
The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes
Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…Abstract Number: 1396 • 2018 ACR/ARHP Annual Meeting
Factors Associated with Specific Quality of Life Evolution in SLE Patients: A French Prospective Longitudinal Multicenter Study
Background/Purpose: To analyze variables associated with evolution of disease-specific health related quality of life (HRQoL) in systemic lupus erythematosus (SLE) patients. Methods: We conducted a…Abstract Number: 1397 • 2018 ACR/ARHP Annual Meeting
Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study
Background/Purpose: To explore, at an item-level, the effect of disease activity (DA) on disease specific health related quality of life (HRQoL) factors in systemic lupus…Abstract Number: 1404 • 2018 ACR/ARHP Annual Meeting
Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort
Background/Purpose: Recent studies have demonstrated the reliability and validity of the NIH PROMIS (Patient-Reported Outcomes Measurement Information System) measures in SLE. Analyses of their responsiveness…Abstract Number: 1696 • 2018 ACR/ARHP Annual Meeting
Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico
Background/Purpose: On September 20, 2017, Puerto Rico was devastated by Hurricane Maria causing severe damage to the Island infrastructure and essential services such as electricity,…Abstract Number: 2439 • 2018 ACR/ARHP Annual Meeting
A Description of Contraception Practices in the Ohio State University Lupus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease, which predominantly affects women and reaches peak incidence during reproductive years. Periods of high…Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status
Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…Abstract Number: 1264 • 2017 ACR/ARHP Annual Meeting
Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests (CATs) in Systemic Lupus Erythematosus (SLE)
Background/Purpose: PROMIS CATs are precise measures of quality of life with construct validity in SLE. The longitudinal responsiveness (sensitivity to change) of PROMIS CATs in…Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting
Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus
Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…Abstract Number: 3233 • 2016 ACR/ARHP Annual Meeting
Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests
Background/Purpose: Poor SLE outcomes have been associated with certain clinical and socio-demographic characteristics, but the determinants of patient reported outcomes (PROs) in SLE are unknown.…Abstract Number: 2836 • 2014 ACR/ARHP Annual Meeting
Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: To conduct secondary endpoint analyses of the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on patient-reported outcomes and…